## Consolidated Statements of Operations (In US dollars)

		Year ended December 31,			
	Notes	2004	2003	2002	
Sales	20	\$974,664,696	\$365,823,504	\$50,315,345	
Cost of sales		709,805,644	357,701,498	103,110,116	
Cost of sales — Amortization of deferred					
stock compensation	17	11,595,131	5,539,275	2,127,822	
Gross profit (loss)		253,263,921	2,582,731	(54,922,593)	
			_,	(0.1,022,000)	
Operating expenses:					
Research and development		78,167,336	32,070,123	37,459,380	
General and administrative		46,015,039	27,911,791	17,781,998	
Selling and marketing		8,129,592	9,446,819	4,371,243	
Litigation settlement	22	23,153,105	_	—	
Amortization of deferred stock					
compensation*	17	15,415,947	5,900,239	1,769,105	
Total operating expenses		170,881,019	75,328,972	61,381,726	
Income (loss) from operations	25	82,382,902	(72,746,241)	(116,304,319)	
	20	,,	(12,1.10,2.1.)	(110,001,010)	
Other income (expense):					
Interest income		10,587,244	5,615,631	10,980,041	
Interest expense		(13,697,894)	(1,424,740)	(176,091)	
Foreign currency exchange gain		8,217,567	1,522,661	247,407	
Others, net		2,441,057	888,189	2,650,049	
Total other income, net		7,547,974	6,601,741	13,701,406	
Income (loss) before income tax		89,930,876	(66,144,500)	(102,602,913)	
Income tax — current	15	186,044			
Net income (loss)		89,744,832	(66 144 500)	(102,602,913)	
		09,744,032	(66,144,500)	(102,002,913)	
Deemed dividends on preference shares	27	18,839,426	37,116,629		
	<u> </u>	10,000,420	07,110,029		
Income (loss) attributable to holders of					
ordinary shares		\$70,905,406	\$(103,261,129)	\$(102,602.913)	
		,,,,,	Ţ( · · · · , = 0 · , · = 0)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

## Consolidated Statements of Operations (In US dollars)

		Year ended December 31,			
	Notes	2004	2003	2002	
Income (loss) per share, basic	18	\$0.01	\$(1.14)	\$(1.27)	
Income (loss) per share, diluted	18	\$0.00	\$(1.14)	\$(1.27)	
Shares used in calculating basic income					
(loss) per share	18	14,199,163,517	90,983,200	80,535,800	
Shares used in calculating diluted income					
(loss) per share	18	17,934,393,066	90,983,200	80,535,800	
* Amortization of deferred stock					
compensation related to:					
				<b>*7</b> 0 / <b>5</b> 00	
Research and development		\$5,138,402	\$2,842,775	\$794,506	
General and administrative		8,023,343	1,793,185	569,419	
Selling and marketing		2,254,202	1,264,279	405,180	
Total		\$15,415,947	\$5,900,239	\$1,769,105	

The accompanying notes are an integral part of these consolidated financial statements.